Loading patent…
AssigneeRutgers, The State University of New Jersey
InventorsRichard H. Ebright, David Degen, Katherine Y. Ebright
Estimating the term…
It has been discovered that the Sal target represents a new and promising target for antibacterial drug discovery. The Sal target is distinct from the rifamycin target and from the CBR703 target. This indicates that antibacterial compounds that function through the Sal target should exhibit no, or minimal, cross-resistance with rifamycins and CBR703. This further implies that it should be possible to co-administer antibacterial compounds that function through the Sal target together with a rifamycin, together with CBR703, or together with both a rifamycin and CBR703, in order to achieve additive or synergistic antibacterial effects and in order to suppress or eliminate the emergence of resistance.
A method to treat a bacterial infection in a subject in need thereof, comprising administering to the subject a first compound selected as being an inhibitor of growth of a bacterium by binding to the bridge-helix cap target of an RNA polymerase, and a second compound that inhibits growth of a bacterium by binding to a site other than the bridge-helix cap target of an RNA polymerase.
A composition that comprises salinamide A and a rifamycin and/or CBR703.
Dependencies are inferred from the claim text.